SEC Form 4
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION | |||
OMB APPROVAL | |||
Washington, D.C. 20549 | |||
OMB Number: | 3235-0287 | ||
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | Estimated average burden | ||
hours per response: | 0.5 | ||
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person * | 2. Issuer Name and Ticker or Trading Symbol | 5. Relationship of Reporting Person(s) to Issuer | |||||||||||||||||||||||||||||||||||
Sandrock Alfred | BIOGEN INC.[ BIIB ] | (Check all applicable) | |||||||||||||||||||||||||||||||||||
Director | 10% Owner | ||||||||||||||||||||||||||||||||||||
3. Date of Earliest Transaction (Month/Day/Year) | |||||||||||||||||||||||||||||||||||||
X | Officer (give title | Other (specify | |||||||||||||||||||||||||||||||||||
02/15/2020 | |||||||||||||||||||||||||||||||||||||
(Last) | (First) | (Middle) | below) | below) | |||||||||||||||||||||||||||||||||
BIOGEN INC. | EVP, Research & Development | ||||||||||||||||||||||||||||||||||||
225 BINNEY STREET | |||||||||||||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable | ||||||||||||||||||||||||||||||||||||
Line) | |||||||||||||||||||||||||||||||||||||
(Street) | X Form filed by One Reporting Person | ||||||||||||||||||||||||||||||||||||
CAMBRIDGE | MA | 02142 | Form filed by More than One Reporting | ||||||||||||||||||||||||||||||||||
Person | |||||||||||||||||||||||||||||||||||||
(City) | (State) | (Zip) | |||||||||||||||||||||||||||||||||||
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | |||||||||||||||||||||||||||||||||||||
1. Title of Security (Instr. 3) | 2. Transaction | 2A. Deemed | 3. | 4. Securities Acquired (A) or | 5. Amount of | 6. Ownership | 7. Nature | ||||||||||||||||||||||||||||||
Date | Execution Date, | Transaction | Disposed Of (D) (Instr. 3, 4 and | Securities | Form: Direct | of Indirect | |||||||||||||||||||||||||||||||
(Month/Day/Year) | if any | Code (Instr. | 5) | Beneficially | (D) or Indirect | Beneficial | |||||||||||||||||||||||||||||||
(Month/Day/Year) | 8) | Owned Following | (I) (Instr. 4) | Ownership | |||||||||||||||||||||||||||||||||
Reported | (Instr. 4) | ||||||||||||||||||||||||||||||||||||
(A) or | |||||||||||||||||||||||||||||||||||||
Code | V | Amount | Price | Transaction(s) | |||||||||||||||||||||||||||||||||
(D) | (Instr. 3 and 4) | ||||||||||||||||||||||||||||||||||||
Common Stock | 02/15/2020 | M | 1,213 | A | $0 | 15,019.2451 | D | ||||||||||||||||||||||||||||||
Common Stock | 02/15/2020 | F | 538 | D | $333 | 14,481.2451 | D | ||||||||||||||||||||||||||||||
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned | |||||||||||||||||||||||||||||||||||||
(e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||||||||||||||||||||||||
1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | 5. Number | 6. Date Exercisable and | 7. Title and Amount | 8. Price | 9. Number of | 10. | 11. Nature | ||||||||||||||||||||||||||
Derivative | Conversion | Date | Execution Date, | Transaction | of | Expiration Date | of Securities | of | derivative | Ownership | of Indirect | ||||||||||||||||||||||||||
Security | or Exercise | (Month/Day/Year) | if any | Code (Instr. | Derivative | (Month/Day/Year) | Underlying | Derivative | Securities | Form: | Beneficial | ||||||||||||||||||||||||||
(Instr. 3) | Price of | (Month/Day/Year) | 8) | Securities | Derivative Security | Security | Beneficially | Direct (D) | Ownership | ||||||||||||||||||||||||||||
Derivative | Acquired | (Instr. 3 and 4) | (Instr. 5) | Owned | or Indirect | (Instr. 4) | |||||||||||||||||||||||||||||||
Security | (A) or | Following | (I) (Instr. 4) | ||||||||||||||||||||||||||||||||||
Disposed | Reported | ||||||||||||||||||||||||||||||||||||
of (D) | Transaction(s) | ||||||||||||||||||||||||||||||||||||
(Instr. 3, 4 | (Instr. 4) | ||||||||||||||||||||||||||||||||||||
and 5) | |||||||||||||||||||||||||||||||||||||
Amount | |||||||||||||||||||||||||||||||||||||
or | |||||||||||||||||||||||||||||||||||||
Number | |||||||||||||||||||||||||||||||||||||
Date | Expiration | of | |||||||||||||||||||||||||||||||||||
Code | V | (A) | (D) | Exercisable | Date | Title | Shares | ||||||||||||||||||||||||||||||
Restricted | $0 | 02/15/2020 | M | 1,213 | (1) | 02/15/2020 | Common | 1,213 | $0 | 915 | D | ||||||||||||||||||||||||||
Stock Unit | Stock | ||||||||||||||||||||||||||||||||||||
Restricted | $0 | 02/15/2020 | J | 915(2) | (1) | 02/15/2020 | Common | 915 | $0 | 0 | D | ||||||||||||||||||||||||||
Stock Unit | Stock | ||||||||||||||||||||||||||||||||||||
Explanation of Responses:
- The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
- This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
/s/ Suzanne Murray, Attorney in
Fact for Alfred W. Sandrock, 02/19/2020
Jr.
** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
-
Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Attachments
- Original document
- Permalink
Disclaimer
Biogen Inc. published this content on 19 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 February 2020 23:41:07 UTC